Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLDN6 CAR-T first-in-human phase 1/2a trial in CLDN6-positive relapsed or refractory advanced solid tumors
NL-OMON54362Phase 2Recruiting
- Sponsor
- BioNTech SE
- Start
- Sep 2020
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of BNT211 and cldn6 modrna-lpx in Nonhematologic neoplasms and cancer (3 arms), sponsored by BioNTech SE. Primary endpoints: Treatment-emergent adverse events, Dose modification or discontinuation due to TEAEs and 2 more. Started Sep 2020; status: recruiting.
02
Drugs
BNT211cldn6 modrna-lpx
03
Conditions
Nonhematologic neoplasmscancer
Beyond the preview
Go deeper on NL-OMON54362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54362.